The United States Food and Drug Administration (FDA) has approved three drugs for non-prescription, or over-the-counter use via a process called a prescription (Rx)-to-OTC switch, it was reported on Friday.
The FDA approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) intended for the temporary relief of arthritis pain; Pataday Twice Daily Relief (olopatadine HCl ophthalmic solution/drops, 0.1%) intended for the temporary relief of itchy and red eyes due to pollen, ragweed, grass, animal hair or dander; and Pataday Once Daily Relief (olopatadine HCl ophthalmic solution/drops, 0.2%) for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander, for non-prescription use.
The FDA granted the approval of non-prescription Voltaren Arthritis Pain to GlaxoSmithKline plc. Approvals of non-prescription Pataday Twice Daily Relief and Pataday Once Daily Relief was granted to Alcon.
The three products will be marketed in the United States as non-prescription drugs and will no longer be offered as prescription drugs.
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer